Related Articles
Reduced administration of rasburicase for tumor lysis syndrome: A single‑institution experience
Analysis of the incidence of tumor lysis syndrome in patients with hematological malignancies treated with rasburicase
Pharmacokinetics and pharmacodynamics of febuxostat under fasting conditions in healthy individuals
Association between colon diverticula and hemoglobin, triglyceride and uric acid levels
Tumor lysis syndrome in a patient with advanced lung squamous cell carcinoma undergoing combined therapy with a programmed cell death protein 1 inhibitor and first‑line chemotherapy: A case report